TransMedics Group, Inc. Earnings Recaps
Q1 2026
May 7, 2026
Shares dropped 24.9% following the earnings release as investors were clearly disappointed by the cautious outlook and enrollment delays in critical clinical programs, which suggest a deceleration in near-term growth drivers despite solid revenue growth.
Key takeaways
- Total revenue grew 21% year-over-year to $174 million, with U.S. transplant product revenue up 22% and OUS transplant revenue increasing 39%.
- Adjusted operating profit reached $18.1 million, or 10.4% of revenue, reflecting ongoing heavy investment in growth initiatives.
- Enrollment delays in the ENHANCE and DENOVO clinical programs due to competitive reactions have postponed anticipated contributions from these key cardiothoracic growth drivers.
- Introduction of the CHOPS device aims to address clinical trial enrollment challenges and expand the product portfolio, but regulatory clearance is still pending.
- Despite operational progress, the market reacted negatively, signaling concerns over near-term growth sustainability and cautious outlook from management.
Q3 2025
Oct 31, 2025
TransMedics achieved robust Q3 2025 results, with total revenue up 32.2% year-over-year to approximately $144 million, driven by strong growth across all organ segments despite typical seasonal slowdowns.
Key takeaways
- Operating profit soared to $23.3 million, representing over 16% of total revenue, compared to just 4% in Q3 2024.
- Transplant logistics service revenue grew 35% year-over-year, with 21 aircraft currently operational to enhance mission coverage.
- Anticipation builds for the upcoming ENHANCE Heart and DENOVO Lung clinical trials, expected to drive future adoption of OCS technology.
- Expansion into international markets is underway, with plans to launch the first OUS NOP program in Italy and establish strategic regional hubs.